Clinical trial · Observational
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
NCT05921318CI-TRIAL-00067583unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Stem Cell Transplant Complications | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Beijing protocol | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- more than 5/10 HLA-mismatched allo-HSCT
- description
- more than 5/10 HLA-mismatched allo-HSCT
- interventionNames
- Combination Product: Beijing protocol
Primary outcomes (1)
- measure
- 1-year LFS
- timeFrame
- Participants will be followed for an expected average of 1 years
- description
- defined as disease relapse, disease progression or death (whichever occurs first) within 1 year from the day the patient receives transplantation.
Secondary outcomes (2)
- measure
- 1-year OS
- timeFrame
- Participants will be followed for an expected average of 1 years
- description
- defined as survival rate within 1 year from the day the patient receives transplantation, calculated based on death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * hematologic malignancy patients * patients eligible for the transplantation of allogeneic hematopoietic stem cells; * patients unavailable with HLA matched donor or related haploidentical donor * voluntary participation in this study and signing the informed consent form. Exclusion Criteria: * Patients with the severe infections; * Pregnant or lactating women * Patients who are not eligible for hematopoietic stem cell transplantation; * Patients who are enrolled in other clinical trials within 1 month; * Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study; * Patients unable to properly understand or refusing to accept the informed consent form.
References
Publications (0)
Data not yet available
No reference posted for this study.